What the label lists and what reports show
Dibasic and monobasic side effects
Dibasic and monobasic's FDA label lists its adverse reactions in its own words. FAERS holds 867 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is diarrhoea (64 reports).
- Generic listed
Check it at the source: the dibasic and monobasic FDA label on DailyMed (effective February 28, 2025, Fresenius Kabi USA, LLC); the FDA FAERS public dashboard.
What does the label list?
From the label: adverse reactionsThe following clinically significant adverse reactions are described elsewhere in the labeling: • Aluminum Toxicity [see Warnings and Precautions ( 5.5 )] • Hypomagnesemia [see Warnings and Precautions ( 5.6 )] • Vein Damage and Thrombosis [see Warnings and Precautions ( 5.7 )] The following adverse reactions in Table 5 have been reported in clinical studies or postmarketing reports in patients receiving intravenously administered potassium phosphates. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Source: FDA drug label, Fresenius Kabi USA, LLC, effective February 28, 2025 (SPL set 475f5cd7-45bd-412a-b419-9962585d6cda), via openFDA; the full label on DailyMed
What do FAERS reports show?
867 reports list dibasic and monobasic among the medicines taken, each a report of something that happened, not proof the medicine caused it; 170 are coded as a death and 511 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 23 reactions below, 4 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.
Reports received each year
The 25 most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms
What next?
- Dibasic and monobasic: the full record
- label, generics, price, shortages, recalls
- Report a side effect to the FDA
- MedWatch
- Side effects hub
- the most reported medicines and reactions